Ernexa Therapeutics Inc.
ERNA Healthcare Biotechnology
Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow ERNA
Ernexa Therapeutics Inc. (ERNA) Piotroski F-score
Ernexa Therapeutics Inc.'s Piotroski F-score for fiscal 2024 cannot be worked out: needs three fiscal years.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2019 | 4 | (2.00) |
| FY2018 | 6 | 1.00 |
| FY2017 | 5 | (2.00) |
| FY2016 | 7 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (163.80%) | — | Fail | 0 |
| Positive operating cash flow | (15.84m) | (20.41m) | Fail | 0 |
| Rising return on assets | (163.80%) | — | n/a | — |
| Cash flow above net income | 28.72m | 1.28m | Pass | 1 |
| Falling long-term leverage | 0.00 | — | n/a | — |
| Rising current ratio | 0.80 | 1.46 | Fail | 0 |
| No new shares issued | 36,400 | 14,200 | Fail | 0 |
| Rising gross margin | 83.51% | (247.06%) | Pass | 1 |
| Rising asset turnover | 0.02 | — | n/a | — |
| Piotroski F-score | n/a — needs three fiscal years | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| LIPO Lipella Pharmaceuticals Inc. compare | 3 |
| KALA KALA BIO, Inc. compare | 3 |
| CVKD Cadrenal Therapeutics, Inc. compare | — |
| ERNA Ernexa Therapeutics Inc. | — |
| IOBTQ IO Biotech, Inc. compare | — |
| PBLA Panbela Therapeutics Inc. compare | — |
| PPCB Propanc Biopharma Inc compare | — |
| PMCB Nuvilex Inc. compare | — |
| UNBX UNITY Biotechnology, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover